198 related articles for article (PubMed ID: 32591645)
1. Requirement for LIM kinases in acute myeloid leukemia.
Jensen P; Carlet M; Schlenk RF; Weber A; Kress J; Brunner I; Słabicki M; Grill G; Weisemann S; Cheng YY; Jeremias I; Scholl C; Fröhling S
Leukemia; 2020 Dec; 34(12):3173-3185. PubMed ID: 32591645
[TBL] [Abstract][Full Text] [Related]
2. Synergy of FLT3 inhibitors and the small molecule inhibitor of LIM kinase1/2 CEL_Amide in FLT3-ITD mutated Acute Myeloblastic Leukemia (AML) cells.
Djamai H; Berrou J; Dupont M; Kaci A; Ehlert JE; Weber H; Baruchel A; Paublant F; Prudent R; Gardin C; Dombret H; Braun T
Leuk Res; 2021 Jan; 100():106490. PubMed ID: 33373830
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Vulnerabilities in
Uras IZ; Maurer B; Nebenfuehr S; Zojer M; Valent P; Sexl V
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30544932
[TBL] [Abstract][Full Text] [Related]
4. Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6.
Uras IZ; Walter GJ; Scheicher R; Bellutti F; Prchal-Murphy M; Tigan AS; Valent P; Heidel FH; Kubicek S; Scholl C; Fröhling S; Sexl V
Blood; 2016 Jun; 127(23):2890-902. PubMed ID: 27099147
[TBL] [Abstract][Full Text] [Related]
5. CDK4/6 Inhibitor PD 0332991 Sensitizes Acute Myeloid Leukemia to Cytarabine-Mediated Cytotoxicity.
Yang C; Boyson CA; Di Liberto M; Huang X; Hannah J; Dorn DC; Moore MA; Chen-Kiang S; Zhou P
Cancer Res; 2015 May; 75(9):1838-45. PubMed ID: 25744718
[TBL] [Abstract][Full Text] [Related]
6. Systems Biology for Drug Target Discovery in Acute Myeloid Leukemia.
Novikova S; Tolstova T; Kurbatov L; Farafonova T; Tikhonova O; Soloveva N; Rusanov A; Zgoda V
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731835
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib suppresses self-renewal and leukemogenesis of leukemia stem cell by NF-ĸB-dependent inhibition of CDK6 in MLL-rearranged myeloid leukemia.
Zhou B; Qin Y; Zhou J; Ruan J; Xiong F; Dong J; Huang X; Yu Z; Gao S
J Cell Mol Med; 2021 Mar; 25(6):3124-3135. PubMed ID: 33599085
[TBL] [Abstract][Full Text] [Related]
8. Aberrant expression of NKL homeobox genes HMX2 and HMX3 interferes with cell differentiation in acute myeloid leukemia.
Nagel S; Pommerenke C; Meyer C; MacLeod RAF; Drexler HG
PLoS One; 2020; 15(10):e0240120. PubMed ID: 33048949
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of CDK4/6 and autophagy synergistically induces apoptosis in t(8;21) acute myeloid leukemia cells.
Nakatani K; Matsuo H; Harata Y; Higashitani M; Koyama A; Noura M; Nishinaka-Arai Y; Kamikubo Y; Adachi S
Int J Hematol; 2021 Feb; 113(2):243-253. PubMed ID: 33068248
[TBL] [Abstract][Full Text] [Related]
10. Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition.
Dzama MM; Steiner M; Rausch J; Sasca D; Schönfeld J; Kunz K; Taubert MC; McGeehan GM; Chen CW; Mupo A; Hähnel P; Theobald M; Kindler T; Koche RP; Vassiliou GS; Armstrong SA; Kühn MWM
Blood; 2020 Nov; 136(21):2442-2456. PubMed ID: 32589720
[TBL] [Abstract][Full Text] [Related]
11. An essential pathway links FLT3-ITD, HCK and CDK6 in acute myeloid leukemia.
Lopez S; Voisset E; Tisserand JC; Mosca C; Prebet T; Santamaria D; Dubreuil P; De Sepulveda P
Oncotarget; 2016 Aug; 7(32):51163-51173. PubMed ID: 27323399
[TBL] [Abstract][Full Text] [Related]
12. Requirement for CDK6 in MLL-rearranged acute myeloid leukemia.
Placke T; Faber K; Nonami A; Putwain SL; Salih HR; Heidel FH; Krämer A; Root DE; Barbie DA; Krivtsov AV; Armstrong SA; Hahn WC; Huntly BJ; Sykes SM; Milsom MD; Scholl C; Fröhling S
Blood; 2014 Jul; 124(1):13-23. PubMed ID: 24764564
[TBL] [Abstract][Full Text] [Related]
13. Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors.
Altman JK; Sassano A; Kaur S; Glaser H; Kroczynska B; Redig AJ; Russo S; Barr S; Platanias LC
Clin Cancer Res; 2011 Jul; 17(13):4378-88. PubMed ID: 21415215
[TBL] [Abstract][Full Text] [Related]
14. Constitutive c-jun N-terminal kinase activity in acute myeloid leukemia derives from Flt3 and affects survival and proliferation.
Hartman AD; Wilson-Weekes A; Suvannasankha A; Burgess GS; Phillips CA; Hincher KJ; Cripe LD; Boswell HS
Exp Hematol; 2006 Oct; 34(10):1360-76. PubMed ID: 16982329
[TBL] [Abstract][Full Text] [Related]
15. Discovery of a first-in-class CDK2 selective degrader for AML differentiation therapy.
Wang L; Shao X; Zhong T; Wu Y; Xu A; Sun X; Gao H; Liu Y; Lan T; Tong Y; Tao X; Du W; Wang W; Chen Y; Li T; Meng X; Deng H; Yang B; He Q; Ying M; Rao Y
Nat Chem Biol; 2021 May; 17(5):567-575. PubMed ID: 33664520
[TBL] [Abstract][Full Text] [Related]
16. Preclinical evaluation of AMG 925, a FLT3/CDK4 dual kinase inhibitor for treating acute myeloid leukemia.
Keegan K; Li C; Li Z; Ma J; Ragains M; Coberly S; Hollenback D; Eksterowicz J; Liang L; Weidner M; Huard J; Wang X; Alba G; Orf J; Lo MC; Zhao S; Ngo R; Chen A; Liu L; Carlson T; Quéva C; McGee LR; Medina J; Kamb A; Wickramasinghe D; Dai K
Mol Cancer Ther; 2014 Apr; 13(4):880-9. PubMed ID: 24526162
[TBL] [Abstract][Full Text] [Related]
17. Upregulation of Flt3 is a passive event in Hoxa9/Meis1-induced acute myeloid leukemia in mice.
Staffas A; Arabanian LS; Wei SY; Jansson A; Ståhlman S; Johansson P; Fogelstrand L; Cammenga J; Kuchenbauer F; Palmqvist L
Oncogene; 2017 Mar; 36(11):1516-1524. PubMed ID: 27617578
[TBL] [Abstract][Full Text] [Related]
18. CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia.
Bertoli S; Boutzen H; David L; Larrue C; Vergez F; Fernandez-Vidal A; Yuan L; Hospital MA; Tamburini J; Demur C; Delabesse E; Saland E; Sarry JE; Galcera MO; Mansat-De Mas V; Didier C; Dozier C; Récher C; Manenti S
Oncotarget; 2015 Nov; 6(35):38061-78. PubMed ID: 26515730
[TBL] [Abstract][Full Text] [Related]
19. Proteomic and genetic approaches identify Syk as an AML target.
Hahn CK; Berchuck JE; Ross KN; Kakoza RM; Clauser K; Schinzel AC; Ross L; Galinsky I; Davis TN; Silver SJ; Root DE; Stone RM; DeAngelo DJ; Carroll M; Hahn WC; Carr SA; Golub TR; Kung AL; Stegmaier K
Cancer Cell; 2009 Oct; 16(4):281-94. PubMed ID: 19800574
[TBL] [Abstract][Full Text] [Related]
20. Constitutive activation of Flt3 and STAT5A enhances self-renewal and alters differentiation of hematopoietic stem cells.
Moore MA; Dorn DC; Schuringa JJ; Chung KY; Morrone G
Exp Hematol; 2007 Apr; 35(4 Suppl 1):105-16. PubMed ID: 17379095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
